Dr. Postow on Entrectinib in Melanoma

Michael A. Postow, MD
Published: Wednesday, Nov 15, 2017



Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

Following more comprehensive molecular profiling, there are different genetic fusion events or other types of activating mutations, states Postow. There is a new fusion that has been discovered around NTRK that affects patients with advanced melanoma.

There are some promising strategies being used to target NTRK fusion, such as entrectinib, Postow explains.
 
SELECTED
LANGUAGE


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

Following more comprehensive molecular profiling, there are different genetic fusion events or other types of activating mutations, states Postow. There is a new fusion that has been discovered around NTRK that affects patients with advanced melanoma.

There are some promising strategies being used to target NTRK fusion, such as entrectinib, Postow explains.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x